CI 976 是口服有效的ACAT (酰基辅酶 A: 胆固醇酰基转移酶)选择性抑制剂。它也是LPAT(溶血磷脂酰基转移酶) 抑制剂。它抑制高尔基体相关 LPAT 活性 (IC50=15 μM)。它抑制多种膜运输步骤，包括在内吞和分泌途径中发现的步骤。

CI 976 is a potent orally active and selective ACAT inhibitor(IC50: 73 nM) and a potent lysophospholipid acyltransferase(LPAT) inhibitor. CI 976 inhibits Golgi-associated LPAT activity (IC50: 15 μM) and multiple membrane trafficking steps.

In the chronic cholesterol-fed rat model, CI 976 decreases non-high density lipoprotein (HDL)-cholesterol and increases HDL-cholesterol in rats with pre-established dyslipidemia[4].

114289-47-3

C23H39NO4

393.56

CI 976

DMF:25 mg/ml(63.52 mM)
DMSO:25 mg/ml(63.52 mM)
Ethanol:25 mg/ml(63.52 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years